Differential Estimation of CKD Using Creatinine- Versus Cystatin C–Based Estimating Equations by Category of Body Mass Index
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Backgound Adiposity is associated with cystatin C. Cystatin C-based glomerular filtration rate (GFR) equations may result in the over-estimation of chronic kidney disease (CKD) prevalence at higher body mass index (BMI) levels. Study Design Cross-sectional Setting and Participants 6,709 US adult NHANES III participants. Factor Body mass index Outcome Absolute percent difference in the prevalence of stage 3 or 4 CKD between creatinine- and cystatin C-based estimating equations by level of BMI. Measurements Normal weight, overweight, and obesity were defined as BMI levels of 18.5 to <25.0, 25 to <30.0, and ≥30 kg/m2, respectively. Stage 3 or 4 CKD (eGFR of 15 to 59 ml/min/1.73m2) was defined using the abbreviated creatinine-based Modification of Diet in Renal Disease equation (eGFRMDRD); a cystatin C, age, sex, and race equation (eGFRCysC,age,sex,race); a cystatin C only equation (eGFRCysC); cystatin C≥1.12 mg/L (elevated cystatin C); and an equation incorporating serum creatinine, cystatin C, age, sex, and race (eGFRCr,CysC,age,sex,race). Results The differences in stage 3 or 4 CKD prevalence between eGFRCysC,age,sex,race, eGFRCysC, and elevated cystatin C, separately, and eGFRMDRD were larger at higher BMI levels. Specifically, compared to estimates derived using eGFRMDRD, for normal weight, overweight, and obese participants, the prevalence of stage 3 or 4 CKD was 2.1%, 3.0%, and 6.5% higher, respectively, when estimated by eGFRCysC,age,sex,race (p-trend=0.005); 0.1%, 0.6%, 2.2% higher, respectively, for eGFRCysC (p-trend=0.028); 2.9%, 5.2%, and 9.5% higher, respectively, for elevated cystatin C (p-trend<0.001); and −0.1%, −0.4%, and 0.0% higher, respectively, for eGFRCr,CysC,age,sex,race (p-trend=0.719). Limitations No gold standard measure of GFR was available. Conclusions BMI may influence the prevalence of stage 3 or 4 CKD when cystatin C-based equations are used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Self-citationCathepsin S, a novel biomarker of adiposity: relevance to atherogenesis
Taleb, S., Lacasa, D., Bastard, J., Poitou, C., Cancello, R., Pelloux, V., Viguerie, N., Benis, A., Zucker, J., Bouillot, J., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-3673fje · Cited by 158 · cited 1×
“Laboratory studies have examined xpression of cathepsin S as a new biomarker of diposity and shown that human adipose tissue ecretes and expresses cathepsin S, which is pregulated in obesity.(29) Cystatin C regulates athepsin S activity by acting as an endogenous nhibitor.”
Cited by
Fatty Kidney, Hypertension, and Chronic Kidney Disease: The Framingham Heart Study
Foster, M. C., Hwang, S.-J., Porter, S. A., Massaro, J. M., Hoffmann, U., & Fox, C. S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.175315 · Cited by 356
Self-citationGrubbs, V., Lin, F., Vittinghoff, E., Shlipak, M. G., Peralta, C. A., Bansal, N., Jacobs, D. R., Siscovick, D. S., Lewis, C. E., & Bibbins-Domingo, K. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.055 · Cited by 79
Kang, S. H., Cho, K. H., Park, J. W., Yoon, K. W., & Do, J. Y. (2015) · Kidney and Blood Pressure Research · doi:10.1159/000368498 · Cited by 72
Beasley, J. M., Aragaki, A. K., LaCroix, A. Z., Neuhouser, M. L., Tinker, L. F., Cauley, J. A., Ensrud, K. E., Jackson, R. D., & Prentice, R. L. (2011) · The Journal of Nutrition · doi:10.3945/jn.110.135814 · Cited by 26
Metadata
- Authors
- Vupputuri, S., Fox, C. S., Coresh, J., Woodward, M., & Muntner, P.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 53
- Issue
- 6
- Pages
- 993-1001
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2052344974
- Cited by
- 66
- References
- 2
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.